Blackhawk Plastic Surgery and other practices report a significant uptick in body-contouring procedures, directly attributable to the GLP-1 agonist boom. Patients losing 50+ pounds on semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) are seeking skin-tightening, cellulite reduction, and body-sculpting treatments to address loose skin and contour irregularities—a natural follow-on to weight loss.
Market
GLP-1 Weight-Loss Boom Fuels Body-Contouring Volume — Practices Report Surge in Post-Weight-Loss Procedures
Ozempic/Wegovy patients driving demand for skin-tightening and body-sculpting treatments.
GLP-1 weight-loss patients are driving a surge in body-contouring procedures.
For medspa and aesthetic-surgery practices, this represents a new patient acquisition funnel and an opportunity to expand service lines. RF microneedling, monopolar RF, and body-sculpting devices (radiofrequency, ultrasound, or cryolipolysis) are seeing increased utilization. However, the market is time-sensitive: GLP-1 adoption peaked in 2023–2024, and saturation is rising. Practices should evaluate their device mix and staffing capacity now. The body-contouring surge also attracts new competition—general surgeons and dermatologists are adding these services—so differentiation through clinical outcomes, patient education, and pricing strategy is critical.
Source: original report ↗
Frequently asked questions
What body contouring procedures do GLP-1 weight loss patients want?
Patients losing 50+ pounds on semaglutide or tirzepatide most commonly seek skin-tightening, cellulite reduction, and body-sculpting treatments to address loose skin and contour irregularities. RF microneedling, monopolar RF, and body-sculpting devices using radiofrequency, ultrasound, or cryolipolysis are seeing the highest demand.
How much weight do GLP-1 patients typically lose before seeking body contouring?
Patients typically lose 50+ pounds on GLP-1 medications like Ozempic, Wegovy, Zepbound, or Mounjaro before they pursue body-contouring procedures. This significant weight loss creates loose skin and contour irregularities that drive demand for aesthetic treatments.
Is the GLP-1 body contouring market still growing or saturating?
GLP-1 adoption peaked in 2023–2024 and saturation is now rising, making this a time-sensitive market opportunity. Practices should evaluate their device mix and staffing capacity now, as competition from general surgeons and dermatologists is increasing.
What devices should medspa practices add for post-GLP-1 weight loss patients?
RF microneedling, monopolar RF, and body-sculpting devices (radiofrequency, ultrasound, or cryolipolysis) are the primary technologies seeing increased utilization for this patient population. Practices should evaluate their current device mix and capacity to meet growing demand.
How can medspa practices differentiate in the GLP-1 body contouring market?
Differentiation is critical as general surgeons and dermatologists enter the space. Focus on clinical outcomes, patient education about post-weight-loss body contouring, and competitive pricing strategy to stand out and retain this new patient acquisition funnel.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.